The stock of Capricor Therapeutics Inc (CAPR) has seen a 5.06% increase in the past week, with a 307.33% gain in the past month, and a 330.33% flourish in the past quarter. The volatility ratio for the week is 14.03%, and the volatility levels for the past 30 days are at 20.56% for CAPR. The simple moving average for the past 20 days is 23.14% for CAPR’s stock, with a 235.38% simple moving average for the past 200 days.
Is It Worth Investing in Capricor Therapeutics Inc (NASDAQ: CAPR) Right Now?
The 36-month beta value for CAPR is also noteworthy at 4.06. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CAPR is 33.56M, and at present, short sellers hold a 15.61% of that float. The average trading volume of CAPR on October 22, 2024 was 2.78M shares.
CAPR) stock’s latest price update
The stock price of Capricor Therapeutics Inc (NASDAQ: CAPR) has jumped by 9.07 compared to previous close of 18.86. Despite this, the company has seen a gain of 5.06% in its stock price over the last five trading days. globenewswire.com reported 2024-10-18 that SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today the closing of its previously announced underwritten public offering of 5,073,800 shares of its common stock, including the exercise in full of the underwriters’ option to purchase additional shares to cover over allotments, bringing the total gross proceeds to Capricor from the offering to approximately $86.3 million, before deducting underwriting commissions and other offering expenses payable by Capricor. All of the shares of common stock sold in the offering, including the over-allotment, were offered by Capricor. The closing of the offering occurred on October 18, 2024.
Analysts’ Opinion of CAPR
Oppenheimer, on the other hand, stated in their research note that they expect to see CAPR reach a price target of $14. The rating they have provided for CAPR stocks is “Outperform” according to the report published on May 17th, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to CAPR, setting the target price at $8 in the report published on January 05th of the current year.
CAPR Trading at 119.67% from the 50-Day Moving Average
After a stumble in the market that brought CAPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.09% of loss for the given period.
Volatility was left at 20.56%, however, over the last 30 days, the volatility rate increased by 14.03%, as shares surge +244.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +447.07% upper at present.
During the last 5 trading sessions, CAPR rose by +5.06%, which changed the moving average for the period of 200-days by +288.11% in comparison to the 20-day moving average, which settled at $16.70. In addition, Capricor Therapeutics Inc saw 320.65% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAPR starting from Nippon Shinyaku Co Ltd, who purchase 2,798,507 shares at the price of $5.36 back on Sep 20 ’24. After this action, Nippon Shinyaku Co Ltd now owns 7,090,351 shares of Capricor Therapeutics Inc, valued at $14,999,998 using the latest closing price.
Stock Fundamentals for CAPR
Current profitability levels for the company are sitting at:
- -1.1 for the present operating margin
- 0.95 for the gross margin
The net margin for Capricor Therapeutics Inc stands at -1.03. The total capital return value is set at -1.87. Equity return is now at value -392.69, with -66.31 for asset returns.
Based on Capricor Therapeutics Inc (CAPR), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -8.14. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is 0.07.
Currently, EBITDA for the company is -23.01 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 33.7. The receivables turnover for the company is 73.39for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
In summary, Capricor Therapeutics Inc (CAPR) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
